Mainz Biomed Presents New Study Data For ColoFuture And eAArly DETECT Study Performance With Sensitivity For CRC Of 92% And 82% For Advanced Adenomas, Including 95.8% Detection Of High-Grade Dysplasia
Portfolio Pulse from Benzinga Newsdesk
Mainz Biomed presented new study data at the ASCO 2024 Annual Meeting, confirming the high sensitivity of its mRNA biomarkers for detecting colorectal cancer (CRC) and advanced adenomas. The results showed 92% sensitivity for CRC and 82% for advanced adenomas, with 95.8% detection of high-grade dysplasia.
June 03, 2024 | 12:16 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Mainz Biomed presented new data confirming the high sensitivity of its mRNA biomarkers for CRC detection, with 92% sensitivity for CRC and 82% for advanced adenomas. This is the third consecutive confirmation of its performance.
The new data presented at a major oncology conference confirms the high sensitivity of Mainz Biomed's mRNA biomarkers, which is likely to positively impact investor sentiment and the stock price in the short term.
CONFIDENCE 95
IMPORTANCE 90
RELEVANCE 100